Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

- Building on Phase III registration trial of VELCADE and rituximab, Millennium initiates new clinical trial with novel combination of VELCADE with bendamustine and rituximab to further advance treatment of patients

with follicular lymphoma -

CAMBRIDGE, Mass., Feb. 20 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the initiation of a multi-center, Phase II trial to evaluate VELCADE in combination with emerging agent, bendamustine, and current standard of care, rituximab, in patients with relapsed follicular lymphoma, a subset of non-Hodgkin's lymphoma (NHL). This trial is part of the Company's comprehensive development program in NHL, which represents a significant growth opportunity for VELCADE.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"We designed this trial to combine three active agents in NHL with the goal of enhancing the clinical outcomes of this patient population," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "We are hopeful this novel combination will add to the growing body of data that show the potential of VELCADE to be part of the standard of care in follicular lymphoma, similar to what we've seen in multiple myeloma."

The primary endpoint of the open-label trial is complete remission with secondary endpoints including progression free survival and duration of remission. The trial is expected to enroll approximately 75 patients.

In previous studies, VELCADE as a single-agent and as part of combination therapy has shown promising remission rates and time-to-disease progression in patients with NHL. Th
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... 29, 2007-Preliminary results from,the immunotherapeutic cancer study at ... profile for SBG. Furthermore,encouraging responses on cancer development ... treated with SBG in,combination with the monoclonal antibody ... described in the company's report for,the 1st quarter ...
... , * Presentation of efficacy trends from ongoing ... by ESMO for presentation in,press conference , MARTINSRIED, ... Prime Standard: MDG) announces that a case,report from ... will be presented in a press conference held ...
Cached Medicine Technology:Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 2Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 3European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference 2
(Date:7/10/2014)... announcement that the "Mississippi Baby," believed to have been ... have detectable levels of the virus, the Elizabeth Glaser ... but remains hopeful that the scientific breakthrough that allowed ... than two years will continue to help researchers understand ... , "Although we had high hopes that the ...
(Date:7/10/2014)... on aggression, who research issues ranging from child abuse ... Meeting of the International Society for Research on Aggression ... Georgia State University is hosting the prestigious world meeting, ... , "We are excited to be bringing together leading ... help produce fresh ideas about the causes, consequences and ...
(Date:7/10/2014)... the amount of alcoholic beverages consumed, even for ... reduced risk of coronary heart disease, lower body ... a new multi-center study published in The ... of Medicine at the University of Pennsylvania. The ... suggest that consuming light-to-moderate amounts of alcohol (0.6-0.8 ...
(Date:7/10/2014)... known as the "Mississippi baby" an infant seemingly cured ... a prolonged remission of HIV infection in The New ... of HIV after more than two years of not taking ... HIV specialist and researchers involved in the case. ... this young child, the medical staff involved in the child,s ...
(Date:7/10/2014)... students looking to bump up their grade point averages ... time in a library or study hall, but in ... that students who were members of the recreational sports ... and sophomore years had higher GPAs than those who ... with memberships stayed in school longer. An increase of ...
Breaking Medicine News(10 mins):Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:Want a higher GPA in college? Join a gym 2
... Oct. 2-6 microTAS 2011 conference, the premier international ... detection technologies for life science and chemistry, University ... method for separating and safely collecting concentrated volumes ... results resolve the critical technical challenge of isolating ...
... , Oxaliplatin, a platinum-based anticancer drug that,s made enormous ... cause nerve damage that may be permanent and worsens ... described by Johns Hopkins researchers in the September issue ... believed to be the first effort to track oxaliplatin-based ...
... Just like extremely premature babies, infants born between 33 and ... 8 to 9, but in these moderately premature children, lung ... shows. "There has been a lot of research demonstrating ... the lung function of children, but limited data on the ...
... The prescribed use of stimulant medications to treat attention ... 1996 to 2008, according to a study conducted by ... for Healthcare Research and Quality (AHRQ). The study was ... the American Journal of Psychiatry. ADHD ...
... Neglected Tropical Diseases will publish an article emphasizing ... Central Asia on Tuesday, Sept. 27th. According to the ... Vaccine Institute, and Dr. Ken Alibek of Nazarbayev University ... a post-Soviet economic breakdown that may have contributed to ...
... , TUESDAY, Sept. 27 (HealthDay News) -- Many children ... the going gets slow, fiber seems to beat all ... A review of nine studies with 640 children ... no known physical cause, found that fiber supplements were ...
Cached Medicine News:Health News:New UC research promises better collection of prostate cancer cells 2Health News:New UC research promises better collection of prostate cancer cells 3Health News:Popular colorectal cancer drug may cause permanent nerve damage 2Health News:Lung Function of Late Preemies May Improve With Age 2Health News:Prescribed stimulant use for ADHD continues to rise steadily 2Health News:Prescribed stimulant use for ADHD continues to rise steadily 3Health News:Central Asia's hidden burden of neglected tropical diseases 2Health News:Fiber Beats Other Remedies for Constipated Kids, Study Says 2Health News:Fiber Beats Other Remedies for Constipated Kids, Study Says 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: